Visual outcome of accelerated fractionated radiation for advanced sinonasal malignancies employing photons/protons

• Published in: Radiotherapy and oncology 2006-12, Vol.81 (3), p.243-249
• Main Authors: Weber, Damien C., Chan, Annie W., Lessell, Simmons, McIntyre, James F., Goldberg, Saveli I., Bussiere, Marc R., Fitzek, Markus M., Thornton, Allan F., DeLaney, Thomas F.
• Format: Article
• Language: English
• Subjects: Accelerated fractionated radiation; Adult; Aged; Carcinoma, Squamous Cell - complications; Carcinoma, Squamous Cell - radiotherapy; Carcinoma, Transitional Cell - complications; Carcinoma, Transitional Cell - radiotherapy; Dose Fractionation; Eye Diseases - etiology; Female; Follow-Up Studies; Humans; Late visual complications; Male; Middle Aged; Neoplasm Recurrence, Local - complications; Neoplasm Recurrence, Local - radiotherapy; Paranasal sinus cancer; Paranasal Sinus Neoplasms - complications; Paranasal Sinus Neoplasms - radiotherapy; Photons - therapeutic use; Proton beam radiation therapy; Protons - therapeutic use; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Treatment Outcome
• ISSN: 0167-8140; 1879-0887
• DOI: 10.1016/j.radonc.2006.09.009

To investigate the visual outcomes of patients with advanced sinonasal malignancies treated with proton/photon accelerated fractionated radiation (AFR). Between 1991 and 2001, AFR was used to treat 36 patients with advanced stage primary ( n = 33) or recurrent ( n = 3) nasal or paranasal malignant tumors. Full ophthalmologic follow-up was documented. The median dose to the gross tumor volume (GTV) was 69.6 CGE (range 60.8–77). Visual complications were graded according to the National Cancer Institute Common Toxicity Criteria (CTC) and the late effects of normal tissue (LENT) scoring systems. The median follow-up was 52.4 months (range 17–122.8). Thirteen patients developed late visual/ocular toxicity. Cataracts were LENT grade 1 and 3 in 2 patients and 1 patient, respectively. One LENT grade 1 vascular retinopathy and 1 optic neuropathy were also observed. Three and five patients presented with nasolacrimal duct stenosis (CTC grade 2, 2 patients; CTC grade 3, 1 patient) and dry-eye syndrome (CTC grade 1, 1 patient; CTC grade 2, 4 patients), respectively. The 3- and 5-year probability of LENT/CTC grade ⩾2 visual toxicity were 15.8 ± 6.7% and 20.7 ± 7.8%, respectively. AFR for locally advanced nasal cavity and paranasal sinus tumors enables delivery of 70 CGE to the tumor with acceptable ophthalmologic complications.